Christopher Ramsden, M.D.

Investigator

Laboratory of Clinical Investigation / Lipid Mediators, Inflammation, and Pain Unit

NIA

251 Bayview Boulevard
Suite 100
Baltimore, MD 21224

410-558-8369

chris_ramsden@nih.gov

Research Topics

The objectives of the Lipid Mediator, Inflammation, and Pain Unit are: (1) to discover new mediators and mechanisms linking lipids to age-related diseases including chronic pain, cardiovascular and neurodegenerative diseases, and (2) to translate these discoveries into targeted, safe and effective nutrition-based and drug-based treatments. The Unit applies an interdisciplinary, translational approach—comprising randomized controlled trials, non-randomized clinical and postmortem studies, missing data recovery, synthetic and analytical chemistry, animal models, immunohistochemistry, and cellular and ex vivo assays—to achieve these objectives.

Biography

Dr. Ramsden is a Clinical Investigator in the Intramural Program of the NIH, Commander in the Commissioned Corps of the U.S. Public Health Service (PHS), and Adjunct Faculty at UNC-Chapel Hill. After completing a medical internship, and then residency training in Physical Medicine & Rehabilitation at the Rehabilitation Institute of Chicago, he was a clinical research fellow at UNC-Chapel Hill before joining the Intramural Program of the NIAAA in 2009. In 2016, he was appointed to a Clinical Tenure-Track position as the Head of the Lipid Mediator, Inflammation, and Pain Unit, within the Laboratory of Clinical Investigation in the NIA in Baltimore, MD, with a joint Tenure-Track appointment in the Intramural Program of NIAAA in Bethesda, MD. Dr. Ramsden leads an interdisciplinary, translational research program investigating the roles of lipid mediators and lipid-related mechanisms underlying the pathogenesis of age-related diseases, with an emphasis on chronic pain, inflammatory and neurodegenerative conditions. Dr. Ramsden also serves as a Medical Officer on the PHS-1 Rapid Deployment Force team in the Commissioned Corps, and recently deployed to provide medical coverage for the PHS response to Hurricanes Irma and Maria.

Selected Publications

  1. Ramsden CE, Domenichiello AF, Yuan ZX, Sapio MR, Keyes GS, Mishra SK, Gross JR, Majchrzak-Hong S, Zamora D, Horowitz MS, Davis JM, Sorokin AV, Dey A, LaPaglia DM, Wheeler JJ, Vasko MR, Mehta NN, Mannes AJ, Iadarola MJ. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch. Sci Signal. 2017;10(493).

  2. Ramsden CE, Faurot KR, Zamora D, Suchindran CM, Macintosh BA, Gaylord S, Ringel A, Hibbeln JR, Feldstein AE, Mori TA, Barden A, Lynch C, Coble R, Mas E, Palsson O, Barrow DA, Mann JD. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain. 2013;154(11):2441-51.

  3. Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, Davis JM, Ringel A, Suchindran CM, Hibbeln JR. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ. 2016;353:i1246.

  4. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013;346:e8707.

  5. Ramsden CE, Ringel A, Majchrzak-Hong SF, Yang J, Blanchard H, Zamora D, Loewke JD, Rapoport SI, Hibbeln JR, Davis JM, Hammock BD, Taha AY. Dietary linoleic acid-induced alterations in pro- and anti-nociceptive lipid autacoids: Implications for idiopathic pain syndromes? Mol Pain. 2016;12.


This page was last updated on February 15th, 2018